Michael A. Danso, MD | Authors

Commentary (Danso, Seidman): Trastuzumab in Breast Cancer

August 01, 2004

The clinical development of trastuzumab(Herceptin) for thetreatment of HER2-overexpressingbreast cancer has been perhapsthe most important recentadvance in the management of metastaticbreast cancer. In their rigorousand comprehensive review, Emensand Davidson highlight the importanttrials that resulted in the US Food andDrug Administration (FDA) approvalof trastuzumab, discuss combinationchemotherapy options with trastuzumab,and preview promising futurestrategies for combining trastuzumabwith other targeted biologic agents.